9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas

Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas

Estimated reading time: < 1 min

Condition: Lung Cancer

Estimated Enrollment: 10

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Tabulation of toxicity type and grade,  To ascertain if K526-GM vaccines induce immunity to CT antigens commonly expressed in thoracic malignancies.,  To determine if metronomic oral CP and celecoxib reduce the number, percentage and function of CD4+ CD25+ Fox P3+ regulatory T cells (T reg) in peripheral blood of thoracic oncology patients.,

Interventions: Allogeneic Tumor Cell Vaccine (K562), Celecoxib

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: February 9, 2015

Completion Date: March 19, 2015

Last  Posted Date: June 19, 2019

Location: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Website Link: https://ClinicalTrials.gov/show/NCT01143545

Was this article helpful?
Dislike 0